Trevi Therapeutics, Inc. (TRVI) Operating cash flow 2018–2025
Trevi Therapeutics, Inc. (TRVI) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$42.1MFY2025 · since FY2018: -$18.3M → -$42.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$42.1M | -10.0% |
| FY2024 | -$38.3M | -20.6% |
| FY2023 | -$31.7M | -12.5% |
| FY2022 | -$28.2M | +2.7% |
| FY2021 | -$28.9M | +0.2% |
| FY2020 | -$29.0M | -25.6% |
| FY2019 | -$23.1M | -26.3% |
| FY2018 | -$18.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TRVI financial trends
TRVI RevenueTRVI Net incomeTRVI Net marginTRVI Gross profitTRVI Gross marginTRVI Operating incomeTRVI Operating marginTRVI Free cash flowTRVI Capital expendituresTRVI Return on equityTRVI Stock buybacksTRVI Dividends paidTRVI Total assetsTRVI Total liabilitiesTRVI Shareholders’ equityTRVI overview →